Ryuichiro Kanda

11PUBLICATIONS
19CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)AutoimmunityHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

|Mar 09, 2026
Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study.

Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada

|Feb 05, 2026
Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Hidenori Sakai, Koshiro Sonomoto, Shingo Nakayamada

|Dec 31, 2024
Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.

Masanobu Ueno, Shigeru Iwata, Kaoru Yamagata

|Nov 07, 2023
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.

Koshiro Sonomoto, Shingo Nakayamada, Yoshihisa Fujino

|Nov 12, 2022
TGF-β3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus.

Yu Shan, Shingo Nakayamada, Aya Nawata

Pageof 2

Frequent Collaborators

11 joint publications

Yoshiya Tanaka

7 joint publications

Koshiro Sonomoto

6 joint publications

Yasuyuki Todoroki

5 joint publications

Yuya Fujita